RPL37C Antibody

What is RPL37C and how does it differ from RPL37?

RPL37C is a variant of the ribosomal protein L37 family, which functions as a component of the 60S ribosomal subunit. While RPL37 (sometimes referred to as RPL37A) is encoded by the RPL37 gene and has a molecular weight of approximately 11 kDa, RPL37C represents a distinct isoform with unique sequence characteristics . The primary sequence of canonical RPL37 consists of 97 amino acids (MTKGTSSFGKRRNKTHTLCRRCGSKAYHLQKSTCGKCGYPAKRKRKYNWSAKAKRRNTTGTGRMRHLKIVYRRFRHGFREGTTPKPKRAAVAASSSS), and contains zinc finger motifs that contribute to RNA binding and ribosome assembly . When designing experiments, researchers should carefully validate antibody specificity between these related proteins through sequence alignment and immunoblotting.

What are the most reliable applications for RPL37C antibody detection?

Based on validated research protocols, the most reliable applications for RPL37C antibody detection include:

When establishing new detection protocols, always perform antibody titration experiments to determine optimal concentrations for your specific experimental conditions and sample types .

What controls should be included when using RPL37C antibodies?

Methodologically sound experiments with RPL37C antibodies require multiple control types:

• Positive controls: Tissue or cell lysates with known RPL37C expression (e.g., human breast carcinoma tissue for immunohistochemistry)

• Negative controls: Samples where primary antibody is omitted or replaced with isotype-matched IgG (such as Rabbit IgG A82272 or A17360)

• Knockdown/knockout validation: siRNA or CRISPR-mediated depletion of RPL37C to verify antibody specificity

• Peptide competition: Pre-incubation of antibody with immunizing peptide to confirm epitope specificity

These controls help distinguish specific signal from background and authenticate antibody performance across different experimental conditions.

How should I optimize Western blot conditions for RPL37C detection?

For optimal Western blot detection of RPL37C:

• Sample preparation: Extract proteins using RIPA or NP-40 buffer supplemented with protease inhibitors and phosphatase inhibitors if phosphorylated forms are of interest

• Protein loading: Load 20-40 μg of total protein per lane; for detecting low abundance in specific tissues, consider immunoprecipitation before blotting

• Gel percentage: Use 15-18% polyacrylamide gels for better resolution of low molecular weight (11 kDa) proteins

• Transfer conditions: Transfer at 100V for 60 minutes using 0.2 μm PVDF membranes (preferred over nitrocellulose for small proteins)

• Blocking: Block with 5% non-fat dry milk in TBST for 1 hour at room temperature

• Antibody incubation: Dilute primary antibody (1:1000-1:5000) in 5% BSA/TBST and incubate overnight at 4°C

• Detection: Use HRP-conjugated secondary antibodies (such as Goat Anti-Rabbit IgG H&L with HRP conjugation)

For phosphorylation studies, consider using Phos-tag™ gels to improve separation of phosphorylated forms.

What are the key considerations for immunohistochemical detection of RPL37C?

Successful immunohistochemical detection of RPL37C requires:

• Fixation: 10% neutral buffered formalin fixation for 24-48 hours is optimal for preserving epitope accessibility

• Antigen retrieval: Heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) for 20 minutes

• Blocking endogenous peroxidase: Incubate sections with 3% hydrogen peroxide for 10 minutes

• Antibody dilution: Use 1:50-1:100 dilution for paraffin-embedded tissues

• Incubation conditions: Overnight incubation at 4°C in humidified chamber

• Detection system: Biotin-streptavidin or polymer-based detection systems yield cleaner backgrounds

• Counterstaining: Light hematoxylin counterstaining preserves visualization of nuclear details

Include parallel negative controls (isotype-matched IgG substituted for primary antibody) on adjacent sections to distinguish specific staining from background.

How do I establish specificity when working with RPL37C antibodies?

Establishing antibody specificity requires a multi-faceted approach:

• Sequence analysis: Compare the immunogen sequence used for antibody generation with the target protein sequence; for RPL37, antibodies are typically raised against amino acids 21-70 of the human protein

• Cross-reactivity testing: Test antibody reactivity against recombinant RPL37C versus related family members

• Western blot analysis: Confirm single band at expected molecular weight (11 kDa)

• Immunoprecipitation-mass spectrometry: Verify that the immunoprecipitated protein is indeed RPL37C

• Genetic validation: Use CRISPR/Cas9 knockout or siRNA knockdown models to confirm signal disappearance

• Peptide competition: Pre-absorb antibody with excess immunizing peptide to demonstrate signal reduction

Document the validation methods used when reporting results to enhance reproducibility across research groups.

How should I address non-specific banding patterns in Western blots using RPL37C antibodies?

When encountering non-specific bands:

• Optimize antibody concentration: Titrate antibody concentration (typically start with 1:1000-1:5000 for Western blots)

• Modify blocking conditions: Test alternative blocking agents (5% BSA versus 5% milk) or increase blocking time

• Increase washing stringency: Use 0.1% TBST instead of 0.05% and extend washing times to 15 minutes per wash

• Add detergents: Include 0.1-0.5% Triton X-100 or NP-40 in antibody dilution buffer

• Pre-clear lysates: Pre-clear cellular lysates with Protein A/G beads to remove proteins that non-specifically bind immunoglobulins

• Try alternative extraction methods: Compare RIPA versus NP-40 versus urea-based extraction buffers

• Validate with siRNA: Confirm which bands disappear with target knockdown

Remember that post-translational modifications like ubiquitination (K3, K10, K14, K25, K31, K36, K42, K46, K52, K54, K68) and acetylation (K10, K31) can cause mobility shifts and additional bands in RPL37 detection .

How can I accurately differentiate between RPL37 and RPL37C in experimental samples?

Differentiating between these related proteins requires:

• Epitope-specific antibodies: Use antibodies raised against regions with maximum sequence divergence between the two proteins

• Two-dimensional gel electrophoresis: Combine isoelectric focusing with SDS-PAGE to separate based on both molecular weight and isoelectric point

• Immunoprecipitation-mass spectrometry: Identify unique peptide fragments specific to each isoform

• RT-PCR validation: Design primers specific to unique regions of each transcript

• Parallel antibody comparison: Run side-by-side comparisons with antibodies specific to each isoform

When interpreting results, always consider the possibility of cross-reactivity and validate findings using complementary techniques.

What factors might affect RPL37C detection in immunohistochemistry?

Several factors can influence RPL37C detection in tissue sections:

• Fixation duration: Overfixation (>48 hours) can mask epitopes through excessive protein crosslinking

• Antigen retrieval methods: Compare heat-induced (citrate, EDTA, Tris buffers) versus enzymatic retrieval methods

• Section thickness: 4-5 μm sections provide optimal balance between structural preservation and antibody penetration

• Antibody incubation temperature: Room temperature versus 4°C can affect specificity and signal intensity

• Detection system sensitivity: Polymer-based systems often provide greater sensitivity than avidin-biotin methods

• Tissue type variations: Different tissues may require adjusted protocols due to protein expression levels

• Post-translational modifications: Phosphorylation at S50 or methylation at K52 may mask epitopes

When optimizing, change only one variable at a time and maintain careful documentation of all modifications to your protocol.

How can I use RPL37C antibodies for studying ribosome heterogeneity in cancer development?

To investigate ribosome heterogeneity in cancer:

• Co-immunoprecipitation studies: Use RPL37C antibodies to isolate intact ribosomes and analyze associated proteins and RNAs by mass spectrometry and RNA-seq

• Proximity ligation assays: Combine RPL37C antibodies with antibodies against other ribosomal proteins to visualize specific ribosome populations

• Tissue microarray analysis: Apply RPL37C antibodies to cancer tissue microarrays to correlate expression with clinical outcomes

• Polysome profiling: Combine with polysome fractionation to identify RPL37C-containing translating ribosomes

• ChIP-seq approaches: Adapt chromatin immunoprecipitation methods to identify RPL37C associations with specific mRNA populations

Analysis of human breast carcinoma tissue has shown differential RPL37 expression patterns compared to normal tissue, suggesting potential roles in cancer progression .

What are the methodological considerations for studying post-translational modifications of RPL37C?

To investigate post-translational modifications (PTMs):

• PTM-specific antibodies: Use antibodies that recognize specific modifications (e.g., phospho-S50, acetyl-K31)

• Phos-tag™ SDS-PAGE: Employ phosphate-binding tag technology to separate phosphorylated from non-phosphorylated forms

• 2D-PAGE with antibody detection: First dimension separation by isoelectric focusing will resolve differently modified forms

• Mass spectrometry approaches: Use targeted multiple reaction monitoring (MRM) to quantify specific modified peptides

• Inhibitor studies: Apply deacetylase inhibitors (TSA, SAHA) or kinase inhibitors to modulate modification levels

Known RPL37 modifications include phosphorylation (S50), acetylation (K10, K31), methylation (K52), and extensive ubiquitination (multiple lysine residues) , which likely affect protein function and stability.

How can I design experiments to study the role of RPL37C in specialized ribosomes and selective mRNA translation?

To explore RPL37C's role in specialized ribosomes:

• CRISPR-mediated tagging: Introduce epitope tags or fluorescent proteins at the endogenous RPL37C locus

• Translation reporter assays: Measure translation of specific mRNAs following RPL37C depletion or mutation

• Ribosome profiling: Compare ribosome footprints on mRNAs in the presence/absence of RPL37C

• RNA immunoprecipitation: Identify mRNAs preferentially associated with RPL37C-containing ribosomes

• Cryo-EM structural analysis: Examine structural differences between ribosomes with and without RPL37C

Zinc-finger motifs in RPL37 suggest potential RNA-binding capabilities that may contribute to selective mRNA recognition or structural roles in ribosome assembly.

What storage and handling protocols maximize RPL37C antibody performance over time?

To maintain antibody performance:

• Storage temperature: Store at -20°C for long-term preservation; avoid repeated freeze-thaw cycles by preparing single-use aliquots

• Short-term storage: Keep at 4°C for up to 2 weeks during active use periods

• Formulation buffer: Maintain in phosphate-buffered saline (pH 7.4) with 150mM NaCl, 0.02% sodium azide, and 50% glycerol for stability

• Thawing protocol: Thaw aliquots slowly on ice rather than at room temperature

• Centrifugation step: Briefly centrifuge antibody solution after thawing to collect all liquid and remove any aggregates

• Contamination prevention: Use sterile technique when handling antibody solutions

• Transportation conditions: Transport at ambient temperature for short periods is acceptable, but longer shipping should occur at 4°C

Implement quality control testing at regular intervals to confirm retention of specificity and sensitivity.

How should I standardize RPL37C antibody-based assays across different experimental batches?

For consistent results across experiments:

• Reference standards: Include a common positive control sample across all experiments

• Antibody lot testing: Compare performance between antibody lots using standard samples

• Calibrated loading controls: Use housekeeping proteins (β-actin, GAPDH) or total protein staining (Ponceau S, SYPRO Ruby)

• Standardized protocols: Document detailed protocols including exact buffer compositions, incubation times, and temperatures

• Image acquisition parameters: Maintain consistent exposure settings, gain, and offset values for imaging

• Quantification methods: Apply consistent analysis regions and background subtraction methods

• Internal reference samples: Include a standard curve in each experiment for quantitative comparisons

When publishing, report antibody catalog numbers, lot numbers, dilutions, and validation methods to promote reproducibility.